Kalpathy-Cramer, Jayashree
Chandra, Vyshak
Da, Xiao
Ou, Yangming
Emblem, Kyrre E.
Muzikansky, Alona
Cai, Xuezhu
Douw, Linda
Evans, John G.
Dietrich, Jorg
Chi, Andrew S.
Wen, Patrick Y.
Stufflebeam, Stephen
Rosen, Bruce
Duda, Dan G.
Jain, Rakesh K.
Batchelor, Tracy T.
Gerstner, Elizabeth R.
Funding for this research was provided by:
AVEO Pharmaceuticals
National Cancer Institute (P01CA80124, U24CA180918, U01CA154601)
Article History
Received: 11 August 2016
Accepted: 9 November 2016
First Online: 16 November 2016
Compliance with ethical standards
:
: R. K. J. owns equity in Enlight, Ophthotech, SynDevRx, and XTuit and serves on the Board of Directors of XTuit and the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, and Tekla World Healthcare Fund, and received grants from MedImmune and Roche. D. G. D. received grants from Merrimack, Bayer and HealthCare Pharmaceuticals.